Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erie Indemnity stock logo
ERIE
Erie Indemnity
$415.56
+1.1%
$410.38
$345.09
$547.00
$19.20B0.39135,600 shs156,367 shs
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$15.21
+1.7%
$15.95
$12.05
$18.45
$22.22B1.0716.86 million shs16.51 million shs
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$31.28
+0.4%
$32.49
$24.05
$34.20
$18.03B0.473.13 million shs4.64 million shs
Ventas, Inc. stock logo
VTR
Ventas
$69.39
+0.2%
$65.59
$41.45
$71.04
$30.33B1.372.59 million shs6.05 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erie Indemnity stock logo
ERIE
Erie Indemnity
+1.11%-0.93%-7.59%+1.48%+3.65%
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
+1.74%-0.33%-6.05%-6.34%+11.84%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
+0.35%-0.89%-7.62%+21.29%+6.25%
Ventas, Inc. stock logo
VTR
Ventas
+0.13%+1.92%-1.32%+19.72%+62.32%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Erie Indemnity stock logo
ERIE
Erie Indemnity
1.593 of 5 stars
0.02.04.20.00.61.71.9
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
4.9074 of 5 stars
3.43.03.33.63.42.52.5
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
4.8767 of 5 stars
3.53.02.53.74.01.72.5
Ventas, Inc. stock logo
VTR
Ventas
4.1838 of 5 stars
2.52.01.73.63.72.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Erie Indemnity stock logo
ERIE
Erie Indemnity
0.00
N/AN/AN/A
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
2.79
Moderate Buy$18.1819.50% Upside
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
3.00
Buy$41.6032.99% Upside
Ventas, Inc. stock logo
VTR
Ventas
2.92
Moderate Buy$72.905.06% Upside

Current Analyst Ratings Breakdown

Latest RPRX, VTR, HBAN, and ERIE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/24/2025
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $18.00
3/18/2025
Ventas, Inc. stock logo
VTR
Ventas
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$68.00 ➝ $75.00
3/13/2025
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$22.00 ➝ $20.00
3/11/2025
Ventas, Inc. stock logo
VTR
Ventas
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$65.00 ➝ $70.00
3/10/2025
Ventas, Inc. stock logo
VTR
Ventas
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$72.00 ➝ $77.00
3/7/2025
Ventas, Inc. stock logo
VTR
Ventas
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$75.00
3/7/2025
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
3/7/2025
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$18.00 ➝ $18.00
3/7/2025
Ventas, Inc. stock logo
VTR
Ventas
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$71.00 ➝ $73.00
3/7/2025
Ventas, Inc. stock logo
VTR
Ventas
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Erie Indemnity stock logo
ERIE
Erie Indemnity
$3.86B4.97N/AN/AN/A
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$7.39B3.01$1.65 per share9.21$12.24 per share1.24
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$2.26B7.97$3.94 per share7.94$17.94 per share1.74
Ventas, Inc. stock logo
VTR
Ventas
$4.92B6.16$3.24 per share21.41$24.77 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Erie Indemnity stock logo
ERIE
Erie Indemnity
$446.06M$11.4838.8729.06N/A15.16%31.22%21.14%4/24/2025 (Estimated)
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$1.94B$1.2312.379.691.3316.23%11.23%0.99%4/18/2025 (Estimated)
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$858.98M$1.4521.576.442.3137.94%24.40%14.01%5/8/2025 (Estimated)
Ventas, Inc. stock logo
VTR
Ventas
$81.15M$0.19365.2318.802.591.65%0.82%0.32%4/29/2025 (Estimated)

Latest RPRX, VTR, HBAN, and ERIE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Erie Indemnity stock logo
ERIE
Erie Indemnity
$3.19N/AN/AN/A$766.98 millionN/A
4/18/2025N/A
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$0.31N/AN/AN/A$1.89 billionN/A
2/27/2025Q4 2024
Erie Indemnity stock logo
ERIE
Erie Indemnity
$2.76$2.91+$0.15$2.91$925.12 million$924.09 million
2/12/2025Q4 2024
Ventas, Inc. stock logo
VTR
Ventas
-$0.02$0.81+$0.83$0.81$1.25 billionN/A
2/11/2025Q4 2024
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.99$1.15+$0.16$0.35$743.60 millionN/A
1/17/2025Q4 2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$0.31$0.34+$0.03$0.34$1.87 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Erie Indemnity stock logo
ERIE
Erie Indemnity
$5.461.31%+7.18%47.56%36 Years
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$0.624.08%+0.82%50.41%N/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.882.81%+7.30%60.69%N/A
Ventas, Inc. stock logo
VTR
Ventas
$1.922.77%-3.37%1,010.53%N/A

Latest RPRX, VTR, HBAN, and ERIE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/20/2025
Erie Indemnity stock logo
ERIE
Erie Indemnity
quarterly$1.36501.2%4/7/20254/7/20254/22/2025
2/12/2025
Ventas, Inc. stock logo
VTR
Ventas
quarterly$0.483%3/31/20253/31/20254/17/2025
1/17/2025
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
quarterly$0.15503.64%3/18/20253/18/20254/1/2025
1/9/2025
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
quarterly$0.222.8%2/21/20252/21/20253/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Erie Indemnity stock logo
ERIE
Erie Indemnity
N/A
1.56
1.56
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
0.92
0.89
0.88
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
0.64
1.44
1.44
Ventas, Inc. stock logo
VTR
Ventas
1.25
0.85
0.85

Institutional Ownership

CompanyInstitutional Ownership
Erie Indemnity stock logo
ERIE
Erie Indemnity
33.67%
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
80.72%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
54.35%
Ventas, Inc. stock logo
VTR
Ventas
94.18%

Insider Ownership

CompanyInsider Ownership
Erie Indemnity stock logo
ERIE
Erie Indemnity
45.79%
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
0.89%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
18.90%
Ventas, Inc. stock logo
VTR
Ventas
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Erie Indemnity stock logo
ERIE
Erie Indemnity
6,04046.19 million25.04 millionOptionable
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
19,9551.46 billion1.44 billionOptionable
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
80576.45 million477.83 millionOptionable
Ventas, Inc. stock logo
VTR
Ventas
450437.14 million432.77 millionOptionable

Recent News About These Companies

Ventas, Inc. stock logo
Allianz SE Buys New Position in Ventas, Inc. (NYSE:VTR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Erie Indemnity stock logo

Erie Indemnity NASDAQ:ERIE

$415.56 +4.56 (+1.11%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$392.00 -23.56 (-5.67%)
As of 06:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. It provides issuance and renewal services; sales related services, including agent compensation, and sales and advertising support services; underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. The company was incorporated in 1925 and is based in Erie, Pennsylvania.

Huntington Bancshares stock logo

Huntington Bancshares NASDAQ:HBAN

$15.21 +0.26 (+1.74%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$14.69 -0.52 (-3.45%)
As of 06:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Huntington Bancshares Incorporated operates as the bank holding company for The Huntington National Bank that provides commercial, consumer, and mortgage banking services in the United States. The company offers financial products and services to consumer and business customers, including deposits, lending, payments, mortgage banking, dealer financing, investment management, trust, brokerage, insurance, and other financial products and services. It also provides 24-hour grace, asterisk-free checking, money scout, $50 safety zone, standby cash, early pay, instant access, savings goal getter, and Huntington heads up; digitally powered consumer and business financial solutions to consumer lending, regional banking, branch banking, and wealth management customers; direct and indirect consumer loans, as well as dealer finance loans and deposits; and private banking, wealth management and legacy planning through investment and portfolio management, fiduciary administration and trust, institutional custody, and full-service retail brokerage investment services. The company offers equipment financing, asset-based lending, distribution finance, structured lending, and municipal financing solutions, as well as Huntington ChoicePay. In addition, it offers lending, liquidity, treasury management and other payment services, and capital markets; government and non-profits, healthcare, technology and telecommunications, franchises, financial sponsors, and global services; and corporate risk management, institutional sales and trading, debt and equity issuance, and additional advisory services. The company offers its products through a network of channels, including branches and ATMs, online and mobile banking, and through customer call centers to customers in middle market banking, corporate, specialty, and government banking, asset finance, commercial real estate banking, and capital markets. The company was founded in 1866 and is headquartered in Columbus, Ohio.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$31.28 +0.11 (+0.35%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$30.50 -0.78 (-2.49%)
As of 06:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Ventas stock logo

Ventas NYSE:VTR

$69.39 +0.12 (+0.17%)
Closing price 04/2/2025 03:58 PM Eastern
Extended Trading
$68.70 -0.69 (-0.99%)
As of 05:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventas Inc. (NYSE: VTR) is a leading S&P 500 real estate investment trust focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. The Company's growth is fueled by its senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas leverages its unmatched operational expertise, data-driven insights from its Ventas Operational InsightsTM platform, extensive relationships and strong financial position to achieve its goal of delivering outsized performance across approximately 1,400 properties. The Ventas portfolio is composed of senior housing communities, outpatient medical buildings, research centers and healthcare facilities in North America and the United Kingdom. The Company benefits from a seasoned team of talented professionals who share a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.